Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Myriad Genetics (GB:0K3W)
LSE:0K3W
Myriad Genetics (0K3W) Share Price & Analysis
0 Followers
0K3W Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$14.53 - $24.13
Previous Close$18.8
Volume2.00
Average Volume (3M)310.00
Market Cap
$1.68B
Enterprise Value$1.79B
Total Cash (Recent Filing)$86.30M
Total Debt (Recent Filing)$201.40M
Price to Earnings (P/E)-5.9
Beta0.57
Next Earnings
May 02, 2024EPS Estimate
-$0.1Last Dividend Ex-Date
Jun 15, 2009Dividend YieldN/A
Share Statistics
EPS (TTM)-3.20
Shares Outstanding89,874,886
10 Day Avg. Volume10
30 Day Avg. Volume310
Standard Deviation0.18
R-Squared0.17
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)11.62
Price to Sales (P/S)3.63
Price to Cash Flow (P/CF)-7.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.44
Enterprise Value/Gross Profit3.76
Enterprise Value/Ebitda-8.61
Forecast
1Y Price Target
$25.00Price Target Upside32.98% Upside
Rating ConsensusHold
Number of Analyst Covering6
Myriad Genetics News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceMYGN delivered solid revenue growth with a beat versus expectations, signaling strong financial performance.
Operational EfficiencyThe company achieved profitability targets and gross margin improvements, reflecting efficient operations and cost management.
Strategic GrowthMYGN is successfully navigating market dislocations by capturing market share from competitors' exits and challenges.
Bears Say
Financial PerformanceAdjusted gross margins of 69.0% were below the expected 70.6%, indicating profitability pressures.
Revenue ConcernsDespite broad-based strength, HCT revenue was lighter than expectations, suggesting some areas of the business may be underperforming.
Stock OutlookAnalyst remains underweight on the stock due to concerns over the sustainability of recent growth and profitability as new products enter competitive markets.
---
Options Prices
Currently, No data available
---
Ownership Overview
8.01% Insiders
24.69% Mutual Funds
29.26% Other Institutional Investors
38.04% Public Companies and
Individual Investors
0K3W FAQ
What was Myriad Genetics’s price range in the past 12 months?
Myriad Genetics lowest share price was $14.53 and its highest was $24.13 in the past 12 months.
What is Myriad Genetics’s market cap?
Currently, no data Available
When is Myriad Genetics’s upcoming earnings report date?
Myriad Genetics’s upcoming earnings report date is May 02, 2024 which is in 12 days.
How were Myriad Genetics’s earnings last quarter?
Myriad Genetics released its earnings results on Feb 27, 2024. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of $0.014 by $0.026.
Is Myriad Genetics overvalued?
According to Wall Street analysts Myriad Genetics’s price is currently Undervalued.
Does Myriad Genetics pay dividends?
Myriad Genetics pays a Notavailable dividend of $1.75 which represents an annual dividend yield of N/A. See more information on Myriad Genetics dividends here
What is Myriad Genetics’s EPS estimate?
Myriad Genetics’s EPS estimate is -$0.1.
How many shares outstanding does Myriad Genetics have?
Myriad Genetics has 89,874,886 shares outstanding.
What happened to Myriad Genetics’s price movement after its last earnings report?
Myriad Genetics reported an EPS of $0.04 in its last earnings report, beating expectations of $0.014. Following the earnings report the stock price went down -3.619%.
Which hedge fund is a major shareholder of Myriad Genetics?
Among the largest hedge funds holding Myriad Genetics’s share is Glenview Capital Management LLC. It holds Myriad Genetics’s shares valued at 101M.
---
Myriad Genetics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$25.00 (32.98% Upside)
$25.00 (32.98% Upside)
Blogger Sentiment
Bullish
GB:0K3W Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-16.33%
12-Months-Change
Fundamentals
Return on Equity
-31.55%
Trailing 12-Months
Asset Growth
-5.37%
Trailing 12-Months
Company Description
Myriad Genetics
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to asses an individual's risk of developing a disease later in life. The Other segment offers products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients; and also includes corporate services such as finance, human resources, legal, and information technology. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.
---
0K3W Company Deck
---
0K3W Earnings Call
Q4 2024
0:00 / 0:00
---
0K3W Stock 12 Months Forecast
Average Price Target
$25.00
▲(32.98% Upside)
Technical Analysis
Crinetics Pharmaceuticals
―
NeoGenomics
―
Thermo Fisher
―
Quest Diagnostics
―
Myriad Genetics
―
Best Analysts Covering 0K3W
1 Year
1 Year Success Rate
7/13 ratings generated profit
1 Year Average Return
-4.75%
reiterated a sell rating 6 months ago
Copying Derik De Bruin's trades and holding each position for 1 Year would result in 53.85% of your transactions generating a profit, with an average return of -4.75% per trade.
---